Medical marijuana advocates and bureaucrats from regulatory agencies around the world have both been awaiting a statement on the risks and benefits of cannabidiol (CBD) from the World Health Organization's Expert Committee on Drug Dependence (ECDD). Now the assessment on the non-psychoactive cannabinoid is in, and it is encouraging news for those who have been hoping for its removal from Schedule 1, the international designation for drugs with no therapeutic value but high potential for abuse.
Recent comments
7 weeks 3 days ago
11 weeks 3 days ago
12 weeks 3 days ago
12 weeks 4 days ago
33 weeks 4 days ago
37 weeks 5 days ago
39 weeks 2 days ago
39 weeks 3 days ago
51 weeks 5 days ago
1 year 5 weeks ago